Racing against the clock, Stada Arzneimittel AG's executive board has voiced worry that the second takeover offer from two private equity suitors will also fail, leaving the German generics maker without a clear future.
With the deadline for acceptances just days away, Stada's leadership has issued an open letter imploring shareholders not to sit...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?